Arcus Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-12-31 was 22.99K shares, a 236.88% increase year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-09-30 was 1.05K shares.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-06-30 was 18.70K shares, a 261.65% increase year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-03-31 was 69.00 shares, a 99.99% decline year-over-year.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 400.00K shares, a 33.33% increase from fiscal 2024.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 300.00K shares, a 0.00% change from fiscal 2023.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 300.00K shares, a 78.57% decline from fiscal 2022.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.40M shares, a 105.65% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 400.00K shares 10-K · filed 2026-02-25 | |
| 2024-12-31 | 300.00K shares 10-K · filed 2025-02-25 | |
| 2023-12-31 | 300.00K shares 10-K · filed 2024-02-21 | |
| 2022-12-31 | 1.40M shares 10-K · filed 2023-02-28 | |
| 2021-12-31 | 680.75K shares 10-K · filed 2022-02-23 | |
| 2020-12-31 | 392.52K shares 10-K · filed 2021-02-25 | |
| 2019-12-31 | 22.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | 41.76K shares 10-K · filed 2020-03-05 |
| 2019-09-30 | 1.05K shares 10-Q · filed 2019-11-05 | 26.65K shares derived: sum of 4 quarters · filed 2019-11-05 |
| 2019-06-30 | 18.70K shares 10-Q · filed 2019-08-06 | 25.59K shares derived: sum of 4 quarters · filed 2019-11-05 |
| 2019-03-31 | 69.00 shares 10-Q · filed 2019-05-02 | 12.06K shares derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-12-31 | 6.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | 720.76K shares 10-K · filed 2019-03-05 |
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-05 | |
| 2018-06-30 | 5.17K shares 10-Q · filed 2019-08-06 | |
| 2018-03-31 | 708.76K shares 10-Q · filed 2019-05-02 | |
| 2017-12-31 | 643.02K shares 10-K · filed 2019-03-05 | |
| 2016-12-31 | 637.11K shares 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |